GoodRx Stock Could Get a Major Trump Boost. Should You Buy It Here? With a potential TrumpRx partnership, should investors buy GDRX stock now? Barchart · Oct 22, 2025
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch Prescription savings platform GoodRx Holdings Inc. (NASDAQ:GDRX) is reportedly joining the so-called TrumpRx website, signaling an initiative expansion beyond pharmaceutical manufacturers' direct discount programs. Benzinga · Oct 9, 2025
GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On? GoodRx Holdings Inc (NASDAQ:GDRX) shares are pulling back Tuesday morning, as investors potentially take profits following Monday’s surge. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk to expand access to popular GLP-1 medications. Benzinga · Aug 19, 2025
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide. Benzinga · Aug 19, 2025
GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here? GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again. Barchart · Aug 18, 2025
3 Telemedicine Stocks Making Healthcare More Accessible The telemedicine industry is transforming healthcare with digital platforms, growing consumer demand, and innovative care delivery models. As the sector evolves, telemedicine stocks like Doximity (DOCS), Hims & Hers Health (HIMS), and GoodRx Holdings (GDRX) are well-positioned to capitalize on this trend. Read on…. StockNews.com · Jan 14, 2025
3 Digital Health Companies Enhancing Patient Engagement The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovations. Amid this, Hims & Hers Health (HIMS), GoodRx Holdings (GDRX), and Talkspace (TALK) are strategically positioned to thrive in the sector, making them attractive investment opportunities. Read on…. StockNews.com · Dec 5, 2024
3 Pharma Powerhouses to Boost Your Year-End Investments Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could… StockNews.com · Dec 11, 2023
Under $15 Bargains: 3 Pharma Stocks to Watch The pharmaceutical industry is anticipated to remain resilient, owing to increasing healthcare expenditure. Given this backdrop, it could be wise to watch quality pharma stocks Organon & Co. (OGN), GoodRx Holdings (GDRX), and Viatris (VTRS) trading under $15 now. Read on…. StockNews.com · Nov 17, 2023
3 Resilient Pharma Stocks to Buy This Week Amid rising global medical needs and advancement in technology, the pharma industry is expected to witness robust growth in the coming years. Given this backdrop, resilient pharma stocks such as Spero Therapeutics (SPRO), GoodRx Holdings (GDRX) and Kamada (KMDA) might be solid buys now. Read on. StockNews.com · Oct 26, 2023
3 Pharma Stocks Ready to Shine This Week The pharmaceutical industry is expected to thrive, driven by the increasing need for chronic disease management and the requirements of an aging demographic. Given the industry’s solid prospects, quality pharma stocks Organon (OGN), GoodRx Holdings (GDRX), and Collegium Pharmaceutical (COLL) could be solid buys this week. Read on…. StockNews.com · Oct 10, 2023
3 Pharma Stocks to Buy Now for a Dose of Profit The pharmaceutical sector is expanding due to advanced technologies such as AI and new drug discoveries. Hence, quality pharma stocks GoodRx Holdings (GDRX), Merck & Co. (MRK), and Sanofi (SNY) might be profitable investments right now. Read on. StockNews.com · Sep 6, 2023
GoodRx Shares Tumble As FY22 Guidance Hit By Grocery Chain Prescription Dispute GoodRx Holdings Inc (NASDAQ: GDRX) shares fell after it expects FY22 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable chunk of its grocery prescription business. Benzinga · May 10, 2022
3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on. StockNews.com · Mar 22, 2022
Benzinga · Mar 7, 2022 TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform. TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023. TXMD will also enter into a long-term services agreement to…
Benzinga · Mar 1, 2022 GoodRx Plunges As Q4 Fall Short Of Expectations, Analysts Cut Price Target Consumer-focused digital healthcare, GoodRx Holdings Inc (NASDAQ: GDRX) shares are plunging after the company's
Benzinga · Mar 1, 2022 Why GoodRX Shares Are Plummeting Today GoodRx Holdings Inc (NASDAQ: GDRX) is plunging Tuesday after the company reported worse-than-expected fourth-quarter financial results and issued guidance below estimates.
Benzinga · Mar 1, 2022 Where GoodRx Holdings Stands With Analysts Over the past 3 months, 7 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.